Literature DB >> 1894308

A cluster of mutations in HLA-A2 alpha 2 helix abolishes peptide recognition by T cells.

R J Moots1, M Matsui, L Pazmany, A J McMichael, J A Frelinger.   

Abstract

In order to investigate the regions of HLA-A2 that control peptide-specific cytotoxic T lymphocyte (CTL) recognition, 37 HLA-A2 genes coding for 50 point mutations that span the alpha 2 helix were synthesized by the technique of saturation mutagenesis. Twenty-nine of these genes, which code for 41 point mutations, were transfected into C1R cells and used as targets in cytotoxicity assays, in the presence of influenza-A matrix peptide 58-68 with specific CTL as effectors. All the transfectants were recognized fully by matrix peptide-specific CTL apart from those with amino acid substitutions at positions 152, 154, 155, 156, or 161, which led to a total loss of recognition and those with mutations at residue 27 or a double mutation at 138 and 150, which were recognized in an intermediate manner. The clustering of the crucial residues that emerges may reflect direct interaction of their side-chains with peptide or the CTL receptor.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1894308     DOI: 10.1007/bf00205816

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  43 in total

1.  The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides.

Authors:  A R Townsend; J Rothbard; F M Gotch; G Bahadur; D Wraith; A J McMichael
Journal:  Cell       Date:  1986-03-28       Impact factor: 41.582

2.  The complete primary structure of HLA-Bw58.

Authors:  J P Ways; H L Coppin; P Parham
Journal:  J Biol Chem       Date:  1985-10-05       Impact factor: 5.157

3.  NK susceptibility varies inversely with target cell class I HLA antigen expression.

Authors:  W J Storkus; D N Howell; R D Salter; J R Dawson; P Cresswell
Journal:  J Immunol       Date:  1987-03-15       Impact factor: 5.422

4.  Rapid and efficient site-specific mutagenesis without phenotypic selection.

Authors:  T A Kunkel; J D Roberts; R A Zakour
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

5.  Saturation mutagenesis of a major histocompatibility complex protein domain: identification of a single conserved amino acid important for allorecognition.

Authors:  R Murray; C A Hutchison; J A Frelinger
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

6.  Domain interactions of H-2 class I antigens alter cytotoxic T-cell recognition sites.

Authors:  H Allen; D Wraith; P Pala; B Askonas; R A Flavell
Journal:  Nature       Date:  1984 May 17-23       Impact factor: 49.962

7.  Biology of cloned cytotoxic T lymphocytes specific for lymphocytic choriomeningitis virus. I. Generation and recognition of virus strains and H-2b mutants.

Authors:  J A Byrne; R Ahmed; M B Oldstone
Journal:  J Immunol       Date:  1984-07       Impact factor: 5.422

8.  Analysis of the molecular basis of HLA-A3 recognition by cytotoxic T cells using defined mutants of the HLA-A3 molecule.

Authors:  M L Jelachich; E P Cowan; R V Turner; J E Coligan; W E Biddison
Journal:  J Immunol       Date:  1988-08-15       Impact factor: 5.422

9.  Identification by site-directed mutagenesis of amino acid residues contributing to serologic and CTL-defined epitope differences between HLA-A2.1 and HLA-A2.3.

Authors:  K T Hogan; C Clayberger; E J Bernhard; S F Walk; J P Ridge; P Parham; A M Krensky; V H Engelhard
Journal:  J Immunol       Date:  1988-10-01       Impact factor: 5.422

10.  Evidence of widespread binding of HLA class I molecules to peptides.

Authors:  J A Frelinger; F M Gotch; H Zweerink; E Wain; A J McMichael
Journal:  J Exp Med       Date:  1990-09-01       Impact factor: 14.307

View more
  9 in total

1.  A biochemical and structural analysis of genetic diversity within the HLA-A*11 subtype.

Authors:  Lenong Li; Weifeng Chen; Marlene Bouvier
Journal:  Immunogenetics       Date:  2005-05-04       Impact factor: 2.846

2.  Limited regions of the alpha 2-domain alpha-helix control anti-A2 allorecognition: an analysis using a panel of A2 mutants.

Authors:  G Lombardi; M Matsui; R Moots; G Aichinger; S Sidhu; R Batchelor; J Frelinger; R Lechler
Journal:  Immunogenetics       Date:  1991       Impact factor: 2.846

3.  Amino-terminal alteration of the HLA-A*0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity.

Authors:  R R Pogue; J Eron; J A Frelinger; M Matsui
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

4.  Roles of the six peptide-binding pockets of the HLA-A2 molecule in allorecognition by human cytotoxic T-cell clones.

Authors:  M Matsui; C E Hioe; J A Frelinger
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-15       Impact factor: 11.205

Review 5.  Conformational changes in MHC class I molecules. Antibody, T-cell receptor, and NK cell recognition in an HLA-B7 model system.

Authors:  K D Smith; Z B Kurago; C T Lutz
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

6.  Restoration of CTL recognition of a mutant FMP peptide by a compensatory change in HLA-A2.

Authors:  M Matsui; J A Frelinger
Journal:  Immunogenetics       Date:  1994       Impact factor: 2.846

7.  Allelic variations clustered in the antigen binding sites of HLA-Bw62 molecules.

Authors:  S Y Choo; L A Fan; J A Hansen
Journal:  Immunogenetics       Date:  1993       Impact factor: 2.846

Review 8.  HLA-A29 and Birdshot Uveitis: Further Down the Rabbit Hole.

Authors:  Jonas J W Kuiper; Wouter J Venema
Journal:  Front Immunol       Date:  2020-11-11       Impact factor: 7.561

9.  Nonstimulatory peptide-MHC enhances human T-cell antigen-specific responses by amplifying proximal TCR signaling.

Authors:  Xiang Zhao; Shvetha Sankaran; Jiawei Yap; Chien Tei Too; Zi Zong Ho; Garry Dolton; Mateusz Legut; Ee Chee Ren; Andrew K Sewell; Antonio Bertoletti; Paul A MacAry; Joanna Brzostek; Nicholas R J Gascoigne
Journal:  Nat Commun       Date:  2018-07-13       Impact factor: 14.919

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.